Product Code: DMKC0184311
This Market Spotlight report covers the Neuroendocrine Tumors market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- Datamonitor Healthcare estimates that in 2019, there were approximately 531,400 incident cases of neuroendocrine tumors (NETs) worldwide, and forecasts that number to increase to 639,200 incident cases by 2028. Worldwide, the majority of NETs in 2019 were malignant carcinoid tumors or neuroendocrine carcinomas. The approved drugs in the NETs space focus on targets such as norepinephrine (noradrenaline), radiopharmaceutical, mammalian target of rapamycin/mTORC, tyrosine hydroxylase, somatostatin receptors, FMS-like tyrosine kinase 3, KIT/c-KIT, platelet-derived growth factor receptor, VEGF receptor, ganglioside GD2, and tryptophan hydroxylase. These drugs are predominantly administered via the oral, intravenous, and subcutaneous routes, while one product is available in an intramuscular formulation
- The majority of industry-sponsored drugs in active clinical development for NETs are in Phase I. Therapies in the pipeline for NETs focus on a wide variety of targets. The largest proportion of these therapies are administered intravenously, with the remainder being oral, subcutaneous, intranasal, and intratumoral formulations.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 42.5%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
- There have been only seven licensing and asset acquisition deals involving NET drugs during 2015-20. The $115m exclusive licensing agreement signed in November 2017 between NanoCarrier and VBL Therapeutics for the development, commercialization, and supply of VB-111 in Japan was the only deal with a disclosed value.
- The distribution of clinical trials across Phase I-IV indicates that the majority of trials for NETs have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV.
- The US has a substantial lead in the number of NET clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
- Novartis has the highest number of completed clinical trials for NETs, with 19 trials. Novartis also leads industry sponsors with the highest overall number of clinical trials for NETs, followed by Ipsen.
TABLE OF CONTENTS
- Hepatic artery embolization
- Somatostatin analogs
- Interferon-alpha (IFN-alpha)
- Radiation therapy
- Targeted therapy
- Palliative care
- Incidence methodology
- Disease definition
- Prevalence methodology
RECENT EVENTS AND ANALYST OPINION
- TBR-760 for NETs (January 3, 2019)
KEY REGULATORY EVENTS
- RadioMedix Eyes Priority Review For PET Diagnostic Agent
- University of Iowa PET Center Earns NME Approval
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
CLINICAL TRIAL LANDSCAPE
- Sponsors by status
- Sponsors by phase
- Recent events